Use of oral neomycin as a hypocholesterolemic agent was found to decrease plasma alpha tocopherol levels during a 9-month, randomized, crossover placebo-controlled clinical trial with controlled diet. Pooled data from each treatment sequence showed a placebo α-tocopherol level of 1,896 ± 643 μg/dl, and a neomycin α-tocopherol concentration of 1,449 ± 451 μg/dl (p < .01). When all subjects were on neomycin simultaneously, the level increased to 1,665 ± 614 μg/dl (p < .05 from placebo). Normal plasma α-tocopherol ranges from 400-1,000 μg/dl. Neomycin treatment reduces but does not normalize elevated levels of α-tocopherol found in Type II hyperlipoproteinemia.
|Original language||English (US)|
|Number of pages||7|
|State||Published - 1986|
ASJC Scopus subject areas